Journal of Nanobiotechnology,
Journal Year:
2023,
Volume and Issue:
21(1)
Published: March 29, 2023
Abstract
Background
The
past
few
years
have
witnessed
a
significant
increase
in
research
related
to
plant-derived
extracellular
vesicles
(PDEVs)
biological
and
medical
applications.
Using
biochemical
technologies,
multiple
independent
groups
demonstrated
the
important
roles
of
PDEVs
as
potential
mediators
involved
cell-cell
communication
exchange
bio-information
between
species.
Recently,
several
contents
been
well
identified
PDEVs,
including
nucleic
acids,
proteins,
lipids,
other
active
substances.
These
cargoes
carried
by
could
be
transferred
into
recipient
cells
remarkably
influence
their
behaviors
associated
with
human
diseases,
such
cancers
inflammatory
diseases.
Main
body
abstract
This
review
summarizes
latest
updates
regarding
focuses
on
its
role
nanomedicine
applications,
drug
delivery
strategies
develop
diagnostic
therapeutic
agents
for
clinical
management
especially
like
cancers.
Conclusion
Considering
unique
advantages,
high
stability,
intrinsic
bioactivity
easy
absorption,
further
elaboration
molecular
mechanisms
factors
driving
function
will
provide
new
horizons
treatment
disease.
Cancers,
Journal Year:
2020,
Volume and Issue:
12(3), P. 731 - 731
Published: March 20, 2020
Receptor
tyrosine
kinases
(RTKs)
are
key
regulatory
signaling
proteins
governing
cancer
cell
growth
and
metastasis.
During
the
last
two
decades,
several
molecules
targeting
RTKs
were
used
in
oncology
as
a
first
or
second
line
therapy
different
types
of
cancer.
However,
their
effectiveness
is
limited
by
appearance
resistance
adverse
effects.
In
this
review,
we
summarize
main
features
inhibitors
(RTKIs),
current
use
oncology,
mechanisms
resistance.
We
also
describe
technological
advances
artificial
intelligence,
chemoproteomics,
microfluidics
elaborating
powerful
strategies
that
could
be
providing
more
efficient
selective
small
RTKs.
Finally,
discuss
interest
therapeutic
combination
RTKIs
with
other
for
personalized
treatments,
challenge
effective
less
toxic
off-target
Journal of Hematology & Oncology,
Journal Year:
2020,
Volume and Issue:
13(1)
Published: Oct. 27, 2020
Abstract
Tyrosine
kinases
are
implicated
in
tumorigenesis
and
progression,
have
emerged
as
major
targets
for
drug
discovery.
kinase
inhibitors
(TKIs)
inhibit
corresponding
from
phosphorylating
tyrosine
residues
of
their
substrates
then
block
the
activation
downstream
signaling
pathways.
Over
past
20
years,
multiple
robust
well-tolerated
TKIs
with
single
or
including
EGFR,
ALK,
ROS1,
HER2,
NTRK,
VEGFR,
RET,
MET,
MEK,
FGFR,
PDGFR,
KIT
been
developed,
contributing
to
realization
precision
cancer
medicine
based
on
individual
patient’s
genetic
alteration
features.
dramatically
improved
patients’
survival
quality
life,
shifted
treatment
paradigm
various
solid
tumors.
In
this
article,
we
summarized
developing
history
tumors,
aiming
provide
up-to-date
evidence
clinical
decision-making
insight
future
studies.
Experimental & Molecular Medicine,
Journal Year:
2022,
Volume and Issue:
54(10), P. 1670 - 1694
Published: Oct. 12, 2022
Abstract
Since
the
initial
clinical
approval
in
late
1990s
and
remarkable
anticancer
effects
for
certain
types
of
cancer,
molecular
targeted
therapy
utilizing
small
molecule
agents
or
therapeutic
monoclonal
antibodies
acting
as
signal
transduction
inhibitors
has
served
a
fundamental
backbone
precision
medicine
cancer
treatment.
These
approaches
are
now
used
clinically
first-line
various
human
cancers.
Compared
to
conventional
chemotherapy,
have
efficient
with
fewer
side
effects.
However,
emergence
drug
resistance
is
major
drawback
therapy,
several
strategies
been
attempted
improve
efficacy
by
overcoming
such
resistance.
Herein,
we
summarize
current
knowledge
regarding
agents,
including
classification,
brief
biology
target
kinases,
mechanisms
action,
examples
perspectives
future
development.
